mar feb jan dec nov oct sep fda drugs february warning letter signature genetics seryx is the company that markets an excellent but expensive pharmacogenetics program which will take your blood or cheek cells and analyze your dna for various genotypes which affect how your body metabolizes certain drugs , many of which are psychotropic drugs this information may be used to help a prescriber make decisions about starting dosages or drugs or combinations of drugs to use or avoid this topic is a whole 'nother post i could do , but this type of testing can be used inappropriately quackwatch page , as well anyway , this computer program is considered by the fda to be a device , and it has not applied for fda approval , so the fda is telling it to stop until approval is obtained wellbutrin bupropion medication guides updated pdf versions of medication guides for wellbutrin and wellbutrin sr were updated generic focalin dexmethylphenidate approved only new drugs approved in merrill goozner comments on his blog , gooznews , about the lowering of innovation in the pharma industry fda starts podcasts the fda commissioner , dr andy von eschenbach , has started a series of drug safety oriented podcasts the first one just announces the series go to the xml feed to subscribe adhd drug warnings the fda is requiring all manufacturers of drugs used to treat adhd , including adderall , concerta , ritalin , and strattera , to develop medication guides to warn patients about the risks of cardiovascular sudden death , stroke , heart attack , blood pressure and psychiatric mania , psychosis , aggression side effects vyvanse releases medication guide shire 's vyvanse lisdexamfetamine dimesylate was listed last month before the name was changed from vynase as a new adhd drug it is a prodrug , meaning it is metabolized into an active drug by the body advantages are said to be that it is once daily and that it is less likely to be abused ie , out of drug abusers prefer other stimulants to this one it now has full approval as a schedule ii drug for full prescribing info , see link to label info here changes in nardil phenelzine prescribing info added severe renal impairment or renal disease to list of contraindications added cautions about use in diabetes and added warning about drug interaction with guanethidine ismelin changes in cymbalta duloxetine prescribing info a number of changes were made , though i cannot tell how substantive these were lilly did receive a new indication for the treatment of gad generalized anxiety disorder with cymbalta changes in effexor xr venlafaxine prescribing info the following was added under the precautions section interstitial lung disease and eosinophilic pneumonia associated with venlafaxine therapy have been rarely reported the possibility of these adverse events should be considered in venlafaxine treated patients who present with progressive dyspnea , cough , or chest discomfort such patients should undergo a prompt medical evaluation and discontinuation of venlafaxine therapy should be considered zimulti or acomplia rimonabant review extended this cannibinoid receptor antagonist , which is being reviewed as a weight loss drug you guessed it it blocks the munchies , even if you are not smoking pot , was to have a final decision on approval status on april the review period has been extended to july i reported in november 's update that this drug was approved in mexico the latest proposed brand name is zimulti the hearing for this drug will be held on june , , before the metabolic endocrinologic drugs advisory committee when the background resource documents are ready , they will be found here warning letter provigil modafinil cephalon got slapped for promoting its wakefulness promoting drug indicated for use in narcolepsy , obstructive sleep apnea , and shift work sleep disorder by distributing a document by dr kerasidis which states the drug is effective in multiple sclerosis , parkinson 's , depression , add , and chronic fatigue syndrome interesting , in that this document was provided as testimony to the maryland dept of health and mental hygiene 's committee which is responsible for making decisions about which drugs will be placed on the medicaid formulary list